[Evaluation of the efficacy of subjective symptoms, objective findings, and of a total tear IgE detection kit in diagnosis of allergic conjunctival diseases].
Abstract | PURPOSE: To evaluate the efficacy of subjective symptoms, objective findings, and of a total tear IgE test kit in the diagnosis of allergic conjunctival diseases (ACD). SUBJECTS AND METHODS: RESULTS: The most prevalent subjective symptoms were itching (81.6%) and hyperemia (77.6%). The clinical scores of the objective findings in the patients with SAC, PAC, AKC, VKC and GPC were 16.3 +/- 3.8 (mean +/- SD) points, 16.2 +/- 2.8, 19.8 +/- 6.5, 23.1 +/- 5.3, and 21.4 +/- 3.9, respectively. In the total tear IgE test 72.2% of the ACD patients were positive; i.e., the ratios were 61.9% in SAC, 65.4% in PAC, 80.5% in AKC, 94.7% in VKC, and 75.0% in GPC. In the examination of eosinophils in the 87 ACD patients, 42.5% (37 eyes) were positive, i.e., the ratio was 20.0% in SAC, 36.8% in PAC, 53.3% in AKC, 75.0% in VKC and 33.3% in GPC. The rate of agreement between the total tear IgE test and the examination of eosinophils was kappa = 0.28 (Cohen kappa coefficient). CONCLUSION: Because of the high positive ratio in patients quasi-definitively diagnosed with ACD, we conclude that the total tear IgE test is useful as an auxiliary method for diagnosing ACD.
|
Authors | Jun Shojio, Eiichi Uchio, Nobuyuki Ebihara, Yuichi Ohashi, Shigeaki Ohno, Shigeki Okamoto, Naoki Kumagai, Yoshiyuki Satake, Kenichi Namba, Kazumi Fukagawa, Atsuki Fukushima, Hiroshi Fujishima, Etsuko Takamura |
Journal | Nippon Ganka Gakkai zasshi
(Nippon Ganka Gakkai Zasshi)
Vol. 116
Issue 5
Pg. 485-93
(May 2012)
ISSN: 0029-0203 [Print] Japan |
PMID | 22690539
(Publication Type: English Abstract, Journal Article)
|
Chemical References |
- Reagent Kits, Diagnostic
- Immunoglobulin E
|
Topics |
- Adolescent
- Adult
- Conjunctivitis, Allergic
(diagnosis, physiopathology)
- Female
- Humans
- Immunoglobulin E
(analysis)
- Keratoconjunctivitis
(diagnosis)
- Male
- Reagent Kits, Diagnostic
- Tears
(immunology)
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|